search icon
      blog search icon

      Why GeoVax Labs Inc. (GOVX) Stock been declining since Tuesday’s afternoon session? - Stocks Telegraph

      By Asim Kamal

      Published on

      November 17, 2021

      10:02 AM UTC

      Why GeoVax Labs Inc. (GOVX) Stock been declining since Tuesday’s afternoon session? - Stocks Telegraph

      GeoVax Labs Inc. (GOVX) shares lost 2.09% as of this writing in the pre-market session of Wednesday. GOVX stock plummeted 3.77% in after-hours on Tuesday, November 16, 2021, and closed the daily trading at $4.60. However, in the regular trading session of Tuesday, GOVX’s stock gained 23.83%. GOVX shares have risen 72.56% over the last 12 months, and they have moved up 14.08% in the past week. Over the past three months, the stock has gained 18.61%, while over the past six months, it has plunged 9.64%.

      Let’s see is there any reason behind its negative performance in the after-hours on Tuesday?

      GOVX Cancer Vaccine Patent In US

      On November 16, 2021, the U.S. Patent and Trademark Office issued a patent covering GeoVax Labs, Inc. (GOVX), a vector platform for expressing tumor-associated antigens in virus-like particles (VLPs).

      GeoVax’s initial results with its MVA-VLP-MUC1 immunotherapy candidates have been encouraging.

      GOVX participation in the upcoming conferences

      GeoVax Labs, Inc. will participate at Vaccine World Asia Congress & Global COVID-19 Vaccine Manufacturing & Supply Chain Summit (virtual conference) which is to be held on November 17-18, 2021.

      GOVX will also take part at World Vaccine & Immunotherapy Congress West Coast 2021, San Diego, CA, which is scheduled for November 30 to December 2, 2021.

      GOVX recent financial results

      On November 11, 2021, GeoVax Labs, Inc. (GOVX) announced its financial results for the quarter ended September 30, 2021.

      Q3 2021 financial highlights

      • GOVX grant and collaboration revenues were $30,414 for the three-month ended September 30, 2021, compared to $415,458 for Q3 2020.
      • Total operating expenses were $1.98 million in Q3 2021 compared to $0.85 million in Q3 2020.
      • It suffered a net loss of $1,950,503 or $0.31 per share for Q3 2021 compared to a net loss of $570,648 $0.73 per share for the same period in 2020.
      • As of September 30, 2021, GeoVax had cash balances of $18.1 million compared to $9.9 million on December 31, 2020.

      GOVX & City of Hope agreement for Covid-19 vaccine

      On November 09, 2021, GeoVax Labs Inc. (GOVX) entered into an exclusive license agreement with the City of Hope to further develop and commercialize a multi-antigenic SARS-CoV-2 investigational vaccine.

      The vaccine is being studied in an ongoing Phase 2 clinical trial and shows a strong potential to be used in the general population as a primary and/or general booster vaccine against COVID-19 worldwide.

      GOVX participation in the recent health congress

      GeoVax Labs, Inc. (GOVX) recently participated at the World Vaccine Congress Europe, which was held on October 19-21, 2021, in Barcelona, Spain. The Chief Scientific Officer of GeoVax, Mark J. Newman, PhD, presented the company during the event


      the GeoVax stock went up in the regular trading session due to the Cancer Vaccine Patent In the U.S but there was no reason for its decline in the after-market session.


      More From Stocks telegraph